top of page

G Medical Innovations engages Boustead and Fosun Hani Securities Limited for NASDAQ IPO

G Medical Innovations engages Boustead Securities and Fosun Hani Securities Limited as Joint Financial and Listing Advisors for NASDAQ IPO

Mobile and e-Health company G Medical Innovations (ASX: GMV) (“G Medical” or the “Company”) announced that it has engaged Boustead Securities, LLC (“Boustead”) and Fosun Hani Securities Limited (“Fosun Hani”) as Joint Financial and Listing Advisors to the Company’s planned initial public offering (“IPO”) on the NASDAQ Stock Exchange (“NASDAQ”).

The engagement contemplates that Boustead and Fosun Hani will be acting as co-underwriters, subject to the completion of an effective registration statement, Nasdaq approval, and the execution of a formal underwriting agreement for the Company’s planned IPO in Q3 of 2020.

While the Company advises there is no certainty that a Nasdaq listing will proceed, both Boustead and Fosun Hani will be instrumental as G Medical continues to explore a Nasdaq listing.

CEO and Executive Director Dr Yacov Geva said: “Engaging Boustead and Fosun Hani is an important step to progress the Company’s potential IPO on the NASDAQ. Both parties are incredibly experienced, have strong relationships with investors globally and will assist the Company in its’ objective of enhancing value for its shareholder base.”

Boustead Securities Head of Equity Capital Markets Dan McClory stated: “With the successful rollout of G Medical’s Prizma monitor, a device that connects your health to your smartphone, we are looking forward to bringing a fast-growing, unique company to investors that previously have had limited access to such opportunities.”

About G Medical Innovations

G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

About G Medical products G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals. The ‘Prizma’ Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical’s Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings. For more information on G Medical, please visit

About Boustead Securities, LLC Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit About Fosun Hani Securities Limited Fosun Hani Securities Limited is a wholly-owned subsidiary of Fosun International Limited (HKEx: 00656), a leading global investment group (Fosun Group). Fosun Hani Securities Limited is Fosun Group's integrated financial hub and primary investment arm in Hong Kong. Established in 1987, Fosun Hani Securities Limited is a participant member of The Stock Exchange of Hong Kong Limited. For more information, please visit This press release is not a solicitation or offer to buy or sell securities. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved. Clinical trials are in early stages. Forward-Looking Statements This announcement contains forward-looking statements. Forward-looking statements provide our current expectations or forecasts of future events. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements in this announcement include, but are not limited to, statements regarding our disclosure concerning the Company’s operations, cash flows, financial position and dividend policy.

323 views0 comments


bottom of page